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Abstract Herbal formulations are plant parts used as raw ma-
terials for self-administered pharmaceutical remedies, and
many of them are being sold without any scientific validation
for their potency and efficacy. This research work was aimed at
evaluating the haematopoietic, biochemical, and histologi- cal
effects of Hepacare®, a popularly sold herbal formulation in
Nigeria against carbon tetrachloride (CCl4)-mediated liver dam-
age in rats. Haematological analysis showed significant reduc-
tion (p < 0.05) in haemoglobin, red blood cell, packed cell
volume, and platelet counts in CCl4-treated group when com-
pared with the untreated group. These parameters were howev-
er reversed across the groups treated with the herbal formula-
tion. Levels of alkaline phosphatase (ALP), alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), and total bili-
rubin were significantly (p < 0.05) reduced after treatment of
rats with the formulation which were previously elevated
(p < 0.05) in the CCl4-treated group when compared with the
untreated group. The CCl4-treated group exhibited significantly
different activities in liver SOD and GSH enzymes. The level of
MDAwas lowered in the liver tissue samples of treated rats when
compared with the CCl4-exposed untreated rats. The groups
treated with the formulation showed signs of protection against
this toxicant as evidenced by the absence of necrosis. Hepacare®
showed reversal effects on the previously increased haematolog-
ical parameters and damaged liver tissues with a potential to
ameliorate oxidative stress in hepatic dysfunction.
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Introduction
The use of herbal medicine has been in existence for a rela-
tively long period of time. Herbal formulations are parts of
plants commonly used as raw materials for self-administered
pharmaceutical remedies and as supplementary products in
the general population (Chizzola et al. 2003). Despite the de-
velopment in contemporary medicine, liver diseases remain a
universal health challenge; thus, the search for new drugs is
still an ongoing process. Chemotherapeutic drugs used for
treating liver diseases are insufficient and sometimes come
with side effects. As a result of objectionable side effects of
such drugs, there is a growing need to focus on systemic
research procedures and assess scientific basis for the herbal
formulations with potential hepatoprotective activity
(Baranisrinivasan et al. 2009). There are diverse plants and
herbal formulations that are readily obtainable for treating
liver diseases (Schuppan et al. 1999). Hundreds of commer-
cial herbal formulations with potential hepatoprotective ability
are being sold all round the globe. Hepacare® is used to treat
patients with sickle cell disease; it is also used as protection
against liver damage which may be as a result of incessant
alcohol consumption. According to the manufacturer, one
capsule (250 mg) is to be taken with each meal three times
daily for up to 30 days. Hepacare® is a blend of three plants
which include:Calliandra portoricensis,Uvaria chamae, and
Canarium schweinfurthii. C. portoricensis (Jacq.) is a
flowering recurrent plant belonging to the family
Mimosaceae (Amujoyegbe et al. 2014). It is often used in
folklore medicine as an abortifacient in women (Orishadipe
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et al. 2010) and as a laxative/worm expeller (Agunu et al.
2005). The plant has been reported to have antidiarrhoeal,
antiplasmodic and analgesic, and anticonvulsant activities
(Aguwa and Lawal 1988; Oyebode et al. 2012). U. chamae,
commonly known as finger root or bush banana, belongs to
the family Annonaceae. It is a small tree native to the tropical
rainforest of west and central Africa where it grows in wet and
coastal shrub lands (Okon et al. 2013). It is used to treat fever
and relieve pains in injuries (Obadoni and Ochuko 2001). C.
schweinfurthii Engl. (Burceraceae) commonly known as
‘African canarium’ or ‘African olive’ is a large forest tree
which grows to a height of 150 ft with straight cylindrical bole
of 90 ft. It spreads across the west, east, and central Africa
(Taniguchi et al. 2004). The fruits, stems, and bark are used for
treating coughs, venereal diseases, and exudates. The leaves
and rhizomes are used to increase nervous activity in the body
and also to cure constipation, malaria, sexual infections, rheu-
matism, and diarrhoea (Koudou et al. 2005). The fruit pulp is
made up of 50% oil and often used for the production of
biofuel (Tchiegang 2004; Agbo et al. 1992).
Several herbal formulations have been examined for their
potential hepatoprotective activity against liver damage in ex-
perimental animal models at the expense of other physiolog-
ical activities of the body.
Carbon tetrachloride (CCl4) is a toxic substance that exerts
its toxic effect by altering the endoplasmic reticulum, resulting
in the loss of metabolic enzymes located in the intracellular
structures which has downstream effects on the haematology
of mammals. Moreover, CCl4 is metabolized by the cyto-
chrome P450 system to yield the trichloromethyl free radicals
that disrupt the cell envelope and organelles, resulting in lipid
peroxidation (Bussieres and Habra 1995). The study is there-
fore aimed at examining the effects of Hepacare® on the
blood and verifying the liver protective potential of this drug
in CCl4-mediated hepatic cell damaged rats.
Materials and methods
Source and composition of herbal formulation
Hepacare® is a proprietary blend of the stem bark dried powder
ofC. portoricensis,U. chamae, and C. schweinfurthii and pack-
aged into 250 mg gelatine capsules in ratio 1:3:1, respectively.
The formulation was obtained from a pharmaceutical outlet at
Ikeja, Lagos State, Nigeria in January 2014.
Preparation of herbal formulation
The encapsulated formulations were collected and opened.
The contents of the capsule were further grinded and dissolved
in distilled water and adjusted to 5 ml/kg bw of animals.
Experimental animals
Forty male albino rats purchased from the University of
Agriculture, Abeokuta, Ogun State, Nigeria, ranging from 150
to 200 g were used for the experiment. The rats were kept under
natural light-dark cycle at a controlled temperature and humidity
and held in the animal house of the Biological Science
Department, Covenant University, Ogun State, Nigeria. Feed
and water were given to the animals ad libitum, and they were
allowed to adjust for 2 weeks preceding the experiment. This
research was approved by the Biological Sciences Research
Ethics Committee, Covenant University. All animals were also
treated in line with the National Institutes of Health (NIH) guide-
lines for the use and care of animals in the laboratory (National
Institute of Health (NIH) 2011).
Experimental design
The model described by Adebayo and colleagues was
employed (Adebayo et al. 2014). The choice of the dose was
the unreported LD50 in a pilot study conducted prior to this
experiment. The animals were divided into five groups of
eight rats each. Group A represents the normal control group
and was given only vehicle (distilled water, 1 ml/kg bw) for
7 days. Animals in group B were treated with vehicle for
4 days and with the vehicle and CCl4 (50% solution of CCl4
in olive oil, 2 ml/kg bw) on the fifth, sixth, and seventh days.
The animals in groups C, D, and E were administered with
500, 1000, and 1500 mg/kg bw of the herbal formula, respec-
tively, and distilled water for the first 4 days and with distilled
water, drug, and CCl4 for the remaining 3 days. Prior to dis-
section, the animals were anaesthetized in diethyl ether and
blood samples were obtained via cardiac puncture into
lithium-heparinized containers using a syringe. The blood
was centrifuged at 10,000×gmin−1 for 15 min and the plasma
was stored at −20 °C until required for biochemical assays
(Adebayo et al. 2011). The kidney and liver were immediately
removed, washed with ice-cold 1.15% KCl buffer, and
weighed. Liver homogenate was prepared by 0.1 M Tris
HCl homogenizing buffer at pH 7.5. Samples from the liver
and kidney were fixed with 10% formaldehyde and processed
for histological examination while the liver homogenate was
used for the antioxidant assay.
Haematology
The haematological indices: packed cell volume (PCV),
haemoglobin (Hb), red blood cell (RBC) count, white blood
cell (WBC) count, and platelet (PLT) count were analysed
using an automated haematology system analyser (ADVIA
60 Open Tube, New York, USA).
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Biochemical assay
The test kits for all biochemical indices measured were pro-
cured as obtained from Randox Laboratories, UK. Standard
methods were used to assess the levels of alkaline phosphatase
(ALP) (Tietz et al. 1983), alanine aminotransferase (ALT),
aspartate amino transferase (AST) (Reitman and Frankel
1957), albumin (Doumas et al. 1971), total bilirubin
(Doumas et al. 1973), total protein (Weichselbaum 1946), urea
(Krieg et al. 1986), creatinine (Larsen 1971), and cholesterol
(Zoppi and Fellini 1976).
Antioxidant assays
Proven analytical antioxidant assay techniques were
employed to quantify GSH (reduced glutathione) (Moron
et al. 1979), superoxide dismutase (SOD) (Misra and
Fridovich 1972), and catalase (CAT) (Sinha 1972), whereas
lipid peroxidation was analysed and expressed as the amount
of MDA (malondialdehyde) formed (Niehaus and Samuelson
1968).
Histology
Small pieces of the liver tissues were fixed in 10% formalin
and implanted in liquid paraffin (Aliyu et al. 2007).
Specimens of 5-6 μm thickness stained with haematoxylin
and eosin were examined for histological changes using a
compound microscope.
Statistical analysis
Differences between the control and experimental groups
were deduced using the statistical analysis software package
SPSS (version 13.0) and GraphPad Prism (version 5). One-
way analysis of variance (ANOVA) test was used to compare
between groups. Significant differences were estimated from
post hoc test by employing Tukey. All data were reported as
mean ± SEM; p values less than 0.05 were considered to be
significant.
Results
Haematological studies
Haematological analysis (Fig. 1) showed significant reduction
(p < 0.05) in haemoglobin, red blood cell, packed cell volume,
and platelet counts in the CCl4-treated group when compared
with the untreated control group. These parameters were sig-
nificantly (p < 0.05) reversed across the groups treated with
the herbal formulation. However, white blood cell count in the
animal’s blood was not significantly (p > 0.05) different from
the control groups.
Biochemical studies
ALP, AST, ALT, and total bilirubin levels were significantly
(p < 0.05) elevated in the CCl4 group as compared with the
untreated group. There was however significant reductions
(p < 0.05) across the treated groups in these parameters except
in the levels of ALP and total bilirubin in which the group
dosed with 1500 mg/kg bw of the drug exhibited significant
(p < 0.05) decrease. Although there was a slight increase in the
concentrations of total protein and albumin, it was not statis-
tically different from the control groups (Fig. 2). There was no
significant difference (p > 0.05) in the levels of urea, creati-
nine, and total cholesterol (Fig. 3).
Antioxidant studies
SOD activity was significantly (p < 0.05) depleted in the
CCl4-exposed untreated rats, but the animals treated with the
herbal formulation showed significantly (p < 0.05) increased
activity across the treatment groups. GSH activity was signif-
icantly (p < 0.05) elevated in the group treated with
1500mg/kg bw. The concentrations ofMDAwere significant-
ly (p < 0.05) lowered in the liver tissue samples of all treated
rats when compared with the untreated CCl4-exposed rats
(Fig. 4).
Histological studies
Histopathological assessment of the liver tissues showed
centrilobular necrosis with rats treated with CCl4 alone. As
they were treated with Hepacare®, there was a dose-
dependent reversal effect, leading to reduced sinusoidal dila-
tion and centrilobular fatty degeneration (Fig. 5). Similarly,
the kidney tissues of rats in CCl4-treated group showed acute
tubular necrosis and glomerular widening. But the group treat-
ed with Hepacare® showed a dose-dependent reversal effect
on the kidney tissues, leading to reduced sinusoidal dilation
and centrilobular fatty degeneration across the treatment
group (Fig. 6).
Discussion
The liver is rich in protein which partly consists of antioxi-
dants because of the numerousmetabolic processes it oversees
(Valencia et al. 2001). These antioxidants scavenge the liver
cells of superoxides, hydroxyl radicals, nitric oxides, perox-
ides, and a host of others (Farombi and Owoeye 2011). Since
free radicals are excited by CCl4, radicals formed tend to over-
whelm the radical scavenging activity of certain antioxidants
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found in hepatic cells, thus igniting a cascade of other radicals
that eventually damage the liver (Iwalewa et al. 2005). We
were able to substantiate hepatic damage by the characteristic
increased activity levels of liver function enzymes such as ALT,
AST, and ALP, which were significantly higher (p < 0.05) in
the CCl4 group when compared with the untreated group
(Fig. 2). We observed in our results that Hepacare® was able
to significantly increase the activity levels of SOD and GSH
(p < 0.05), although GSH was only significantly increased in
the group treated with 1500 mg/kg bw while the increase ob-
served for CATwas not statistically significant (p < 0.05) in all
treatment groups when compared alongside with the untreated
and CCl4-treated groups (Fig. 4). The increase in the level of
these antioxidants in Hepacare®-treated rats suggests that in-
creased antioxidant activities of SOD, CAT, and GSH induced
by the herbal formulation were able to ameliorate the hepato-
toxic effect of CCl4 which follows the same pattern in the
observed activity levels of ALT, AST, and ALP in these
groups. These parameters were reduced in Hepacare®-treated
groups; however, ALT level was more significantly lower
(p < 0.05) when compared alongside with the untreated con-
trol group. Our findings are in consistent with the histological
results of the liver tissues where CCl4-treated animals showed
marked centrilobular necrosis but became reduced following
treatment with Hepacare® (Fig. 5). This result is quite similar
with the results obtained by Rhunzi and colleagues using
oroxylin as a hepatoprotective agent (Runzhi et al. 2013).
Certain phytochemicals in the drug formulation are likely to
repress hepatic cell necrosis that could arise from inflammatory
response caused by CCl4 (Taniguchi et al. 2004). Since antiox-
idant enzymes observed are inversely proportional to liver func-
tion enzymes, the reduction in plasma liver function enzymes
mediated byHepacare® herbal formulationmay be attributed to
the increased protein concentration of antioxidant enzymes
mediated by the drug formulation and the individual free rad-
ical scavenging activity of drug component mediated by
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Fig. 1 Effects of Hepacare® on
selected haematological
parameters of albino Wistar rats.
WBC white blood cell, HB
haemoglobin, RBC red blood cell,
PCV packed cell volume.
Values represent
mean ± SEM of eight replicates.
ap < 0.05, significantly different
from the negative control group.
bp < 0.05, significantly different
from the CCl4 control group.
#p < 0.05, the CCl4 control group
significantly different from the
untreated control group
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flavonoids and phenolic compounds present. Radicals that
oxidize membrane lipids have the potential to release
membrane-bound alkaline phosphatase from the endoplasmic
reticulum and plasma membrane of hepatic cells (Ojiako and
Nwajo 2005). This was observed in the amount of lipid per-
oxidation that was found in the CCl4 group. Lipid peroxida-
tion is characterized by the amount of MDA formed when
polyunsaturated fatty acids of biological membranes are oxi-
dized and broken down (Gaweł et al. 2004). Treatment with
Hepacare® reduced the concentration of MDA in a dose-
dependent pattern. Chemoprevention against chemical carcin-
ogens and oxidative stress breakdown and chemical carcino-
gens by natural products may be linked to their antioxidant
status (Farombi and Owoeye 2011). We can also suggest the
presence of certain bioactive components in this herbal formu-
lation that have the ability to induce the expression and synthe-
sis of protein that includes various antioxidant enzymes. Since
plasma total protein points to the viability of hepatic tissues in
mammals, the rise in plasma total protein and albumin in the
entire treated groups, although not significantly different from
the untreated and CCl4-treated groups, could show that the
formulation increased the protein synthesis activity of the liv-
er. This is probably the underlying mechanism for the eleva-
tion of antioxidants observed in the liver cells. This result is in
line with the findings of Sanjay and colleagues on the hepa-
toprotective activities of Amorphophallus companullatus
(Sanjay et al. 2009). Serum total protein basically contains
globulins and albumin which are globular proteins that act
as transporters of xenobiotics. It is therefore important for
the synthesis of these proteins for effective elimination of
the ingested foreign compounds that makes the herbal formu-
lation. Dixon and Paterson reported an association between
body posture and plasma total protein and cholesterol
(Dixon and Paterson 1978). Because the liver of animals in
the CCl4 group was severely damaged, animals in the group
had lower levels and always had a lying posture; these param-
eters were consequently reduced in the group. CCl4-adminis-
tered animals suffer from distress and therefore are unable to
take in fat and protein from dietary sources, thus crumbling
the level of cholesterol in the circulatory system. Hepatic
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Fig. 2 Effects of Hepacare® on
liver functions of albino Wistar
rats. a ALT alanine
aminotransferase. b AST aspartate
aminotransferase. c ALP alkaline
phosphatase. d Total protein. e
Albumin. f Bilirubin. Values
represent mean ± SEM of eight
replicates. ap < 0.05, significantly
different from the negative
control group. bp < 0.05,
significantly different from the
CCl4 control group.
#p < 0.05, the
CCl4 control group significantly
different from the negative
untreated control group
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damage compromises this physical activity (Adedapo et al.
2005). Since the inability to ingest cholesterol triggers its de
novo synthesis which takes place in the liver of mammals to
complement the dietary source, the animals suffer from low
blood levels of cholesterol as a result of damage to the liver.
Hepacare® was able to restore the levels of cholesterol in the
treated groups; however, there was no observed significance
(p > 0.05) in all the experimental groups, but there was a
correlation with protection against liver injury when compared
with observed activity of liver function parameters (Fig. 2).
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Fig. 3 Effects of Hepacare® on
plasma concentration of urea,
creatinine, and cholesterol in
albino Wistar rats. a Urea. b
Creatinine. c Cholesterol. Values
represent mean ± SEM of eight
replicates. ap < 0.05, significantly
different from the negative
control group. bp < 0.05,
significantly different from the
CCl4 control group.
#p < 0.05, the
CCl4 control group significantly
different from the untreated
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Fig. 4 Effects of Hepacare® on
hepatic antioxidant of albino
Wistar rats. a SOD superoxide
dismutase. b GSH reduced
glutathione. c CAT catalase. d
MDA malondialdehyde. Values
represent mean ± SEM of eight
replicates. ap < 0.05, significantly
different from the negative
control group. bp < 0.05,
significantly different from the
CCl4 control group.
#p < 0.05, the
CCl4 control group significantly
different from the untreated
control group
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However, we can also suggest that the increased total protein
and albumin though not significant in the groups administered
with the herbal drug elevated these parameters and other pa-
rameters that readily bind these protein products such as cho-
lesterol (Fig. 3). Total bilirubin is a marker for both hepatic
injury and haemolysis. The increased levels of this parameter
in CCl4-treated group also corroborate the observed liver in-
jury and haematological compromise. Considering this result,
we can infer that the drug formulation attenuated CCl4-in-
uced damage on the hepatobiliary system of mammals in a
concentration-dependent pattern with significant difference
observed in the highest dose of the herbal formulation.
Direct bilirubin leaks out of hepatic tissue into the circulatory
system, thereby increasing the plasma concentration of total
bilirubin, resulting in bilirubin deposits in the urine, skin, and
mucous membrane of the eyes, leading to jaundice (Nyblom
et al. 2004). Results obtained from haematological examina-
tion corroborate the protective effects of Hepacare® against
any form of toxicity by CCl4 (Fig. 1). The observed CCl4-
induced haemolysis was indicated by a reduction in RBC,
Hb, and PCV. The haemolytic condition induced by CCl4
was also proportional to the level of bilirubin observed in this
group which is a product of haemoglobin degradation
(Tiribelli and Ostrow 2005). This haemolysis was then treated
with Hepacare® as shown by a significant (p < 0.05) increase
in PCV, Hb, and RBC in drug-treated groups in these blood
parameters. CCl4 was also observed to impair the formation of
WBC, though not statistically significant (p > 0.05). Low
WBC increases susceptibility to infection from the microen-
vironment and carcinogenesis by CCl4. The ability of WBCs
to carry out a ‘search and arrest rogue cells’ has not in any way
compromised the system (Standish et al. 2008). The liver and
kidney are thus liable to infection and haemorrhage within
days. Hepacare® did not significantly (p > 0.05) alter the level
of the WBC across the treated groups. The platelet count was
significantly (p < 0.05) reduced in the CCl4-treated group,
leading to thrombocytopenia which may probably be due to
decreased production of thrombopoietin. Thrombopoietin is a
glycoprotein produced by the liver and kidney which controls
the production of platelets. It stimulates the differentiation and
production of the bone marrow cells that develop large num-
bers of platelets (Kaushansky 2006). Hepacare® significantly
normalized the platelet counts and thus may act on its mech-
anism of action by stimulating the bone marrow cells for the
a b
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Fig. 5 Photomicrograph of a the
liver of rat in the CCl4-only group
showing centrilobular necrosis
(see the arrow), H&E, ×160; b the
liver of rat treated with CCl4 and
500 mg/kg bw of Hepacare®
showing mild centrilobular fatty
degeneration (see the arrow),
H&E, ×160; c the liver of rat
treated with CCl4 and 1000mg/kg
bw of Hepacare® showing fatty
degeneration and moderate
sinusoidal dilation (see the
arrow), H&E, ×160; d the liver of
rat treated with CCl4 and
1500 mg/kg bw of Hepacare®
showing reduced sinusoidal
dilation and centrilobular fatty
degeneration, H&E, ×640; and e
the liver of rat in the untreated
control showing normal features,
H&E, ×400
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production of this hormone. We also observed that Hepacare®
was able to protect our experimental subjects from nephritic
damage apart from the wide protection it has conferred on the
liver at higher concentrations of the herbal formulation (Fig. 6).
High plasma levels of creatinine and urea could result in the
malfunctioning of cells of the kidney. The kidney is involved in
the excretion of waste via ordered steps of ultrafiltration, selec-
tive reabsorption, and tubular secretion. A compromise of these
activities leads to its damage which is characterized by the
leakage of creatinine and urea out of the nephron. Thus, the
kidney function test parameters such as urea and creatinine
levels were low (but not statistically different) in Hepacare®-
treated groups when compared with the control groups (Fig. 3).
Creatinine resulting from muscle metabolism is usually filtered
out of the plasma by the kidney. Increased plasma level of this
parameter suggests an impairment of the glomerulus. However,
this parameter cannot be measured in isolation because in-
creased creatinine could result from increased muscle mass;
therefore, blood urea nitrogen was measured alongside
creatinine. This was also insignificantly (p > 0.05) low in
drug-treated groups. When the rats were treated with CCl4,
there were acute tubular necrosis and glomerular widening
but subsequent treatment of the animals with Hepacare® espe-
cially at higher doses reduced these necrotic cells of the kidney
(Fig. 6). Thus, Hepacare® was able to protect the animals from
nephritic impairment.
Conclusion
In conclusion, we found Hepacare® to possess strong
favourable effects in rat model against liver impairment and
blood disorders caused by CCl4 and potential toxicants similar
to its mode of action through its high antioxidant-generating
activities. The protective effect of Hepacare® therefore pre-
sents a clinical prospect in the development of novel curative
or corrective agents for acute liver and kidney damage.
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Fig. 6 Photomicrograph of a the
kidney of rats in the untreated
group showing normal
glomerular and tubular histology;
b the kidney of rats in the CCl4-
only-treated group showing acute
tubular necrosis and glomerular
widening (see the arrow); c the
kidney of rat treated with CCl4
and 500 mg/kg bw of Hepacare®
showing focal necrosis of the
proximal convoluted tubular
lining epithelial cells (see the
arrow); d the kidney of rat treated
with CCl4 and 1000 mg/kg bw of
Hepacare® showing that focal
areas of necrosis of the proximal
tubular lining epithelial cells were
still seen along with cellular
swelling, desquamation, and loss
of brush border; and e the kidney
of rat treated with CCl4 and
1500 mg/kg bw of Hepacare®
showing reduced tubular necrosis
and glomerular widening
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